Jazz Pharmaceuticals (NasdaqGS:JAZZ) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsJohn Bluth - Head of Investor RelationsMichael Riad - VPMohit Bansal - Managing DirectorPhil Johnson - EVP and CFORenee Gala - President and CEORob Iannone - EVP of Research and DevelopmentSam Pearce - Chief Commercial OfficerNone - ShareholderConference Call ParticipantsAmi Fadia - Senior AnalystBrian Skorney - Senior Research AnalystDavid Amsellem - Managing Director and Senior Research AnalystDavi ...

Jazz Pharmaceuticals (NasdaqGS:JAZZ) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsJohn Bluth - Head of Investor RelationsMichael Riad - VPMohit Bansal - Managing DirectorPhil Johnson - EVP and CFORenee Gala - President and CEORob Iannone - EVP of Research and DevelopmentSam Pearce - Chief Commercial OfficerNone - ShareholderConference Call ParticipantsAmi Fadia - Senior AnalystBrian Skorney - Senior Research AnalystDavid Amsellem - Managing Director and Senior Research AnalystDavi ...

Jazz Pharmaceuticals (NasdaqGS:JAZZ) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker12Good day, and thank you for standing by. Welcome to the Jazz Pharmaceuticals Fourth Quarter 2025 Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is ...

Supernus Pharmaceuticals (NasdaqGM:SUPN) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker5Good afternoon. Welcome to Supernus Pharmaceuticals for the quarter and full year 2025 financial results conference call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session. Instructions will follow at that time. As a reminder, this conference is being recorded. I would now like to hand the conference over to Peter Vozzo of ICR Healthcare, Investor Re ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - February ...

CORT Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Corcept Therapeutics Inc. [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- [Robbins LLP] reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Ultragenyx a ...

Welcome back to Market on Close. I'm Marley Caden here in Chicago alongside Sam Bodis at the New York Stock Exchange. Some final thoughts on the session from both of us.For me, of course, an update to the saga that I love. The Warner Brothers Discovery acquisition drama back in focus after the company confirmed it received a higher takeover bid from Paramount Skyance, escalating the bidding war with Netflix. Paramount is trying to top Netflix's roughly 2775 per share agreement with its enhanced proposal tha ...

Management characterizes 2025 as a foundational year of disciplined execution, focusing on the central role of C3 inhibition to address complement-driven diseases across ophthalmology and nephrology. SYFOVRE performance in geographic atrophy (GA) is described as resilient, with 17% year-over-year growth in total injections despite revenue being impacted by elevated free goods utilization. The EMPAVELI launch in C3G and primary IC-MPGN is cited as a primary near-term growth engine, achieving over 5% ma ...

PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the upcoming investor conferences in March as follows: UBS European Healthcare Conference Tuesday, March 3, 2026 (investor meetings only – no webcast)Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026, at 10:00 am ET (webcast fireside chat)Barclays 28th Annual Global Healthcare Co ...